Letters, Testimony & Comments

Mon, 2008-10-27 01:00
To whom it may concern: The Food and Drug Administration (FDA) has requested comments relevant to the implementation of Sec. 912 of the Food and Drug Administration Amendments Act of 2007 (FDAAA). Among other things, Sec. 912 generally prohibits...
Mon, 2008-10-27 01:00
Re: SEC Release No. 34-58572 Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments on the proposed rulemaking, SEC Release No. 34-58572, by the Securities and...
Sun, 2008-10-26 23:00
Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments on the proposed rulemaking, SEC Release No. 34-58572, by the Securities and Exchange Commission (“SEC...
Fri, 2008-10-24 01:00
Re: Wholesale Distribution Senate Bill 759 Workgroup: Target Date for Implementation of Electronic Track and Trace Pedigree Technology for Maryland Dear Sir/Madam: The Biotechnology Industry Organization (BIO) appreciates the opportunity to...
Fri, 2008-10-24 01:00
Re: Proposed Rule 603-052-1236: To Establish a System for Review of Federal Permit Applications For Growing Biopharmaceutical Crops In Oregon Dear Ms. Gooch: On behalf of the Biotechnology Industry Organization (BIO), on October 14, 2008, I...
Wed, 2008-10-15 01:00
Re: Interagency Cooperation Under the Endangered Species Act; Proposed Rule; Docket No: FWS-R9-ES-2008-0093 To whom it may concern: This letter is submitted by the Biotechnology Industry Organization (BIO) in response to the request for...
Mon, 2008-10-13 01:00
BIO responds to a recent report entitled "Toward a New Era of Intellectual Property: From Confrontation to Negotiation" which offered no empirical evidence to back up its claim to the contrary.
Mon, 2008-10-06 01:00
Re: Docket No. FDA-2008-D-0417: Draft Guidance for the Public and FDA Staff on Convening Advisory Committee Meetings; Availability   Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug...
Wed, 2008-10-01 01:00
Re: Emerging Health Care Competition and Consumer Issues – Comment, Project No. P083901 (Federal Register, September 3, 2008, Volume 73, Number 171, pp. 51479-51482, “Notice of Public Workshops and Roundtables and Opportunity for...
Fri, 2008-09-26 01:00
Re: Request for Comments regarding the July 30, 2008 CMS Posting of Potential National Coverage Decision Topics Dear Dr. Phurrough: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for...
Fri, 2008-09-26 01:00
Re: OMB control number 0910-0616, Docket No. FDA-2008-N-0144, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification to Accompany Drug, Biological Product, and Device...
Mon, 2008-09-22 01:00
Dear Chairman Cox and Director Thomsen: On behalf of its members, the Biotechnology Industry Organization (“BIO”) would like to commend the Securities and Exchange Commission’s (“SEC”) recent efforts to investigate...
Thu, 2008-09-18 01:00
The letter, signed by approximately 60 patient groups, emphasizes support for restoring eligibility in the SBIR program to venture-backed bioscience companies.
Wed, 2008-09-17 01:00
BIO letter to Senator Robert C. Byrd, Chairman of the Senate Committee on Appropriations